Fighting life-threatening blood cancers and diseases
The EBMT is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patient’s lives.

EBMT Members – more than 4,500 physicians, nurses, scientists and other healthcare professionals – participate in a unique collaborative network of peers involved in haematopoietic stem cell transplantation (HSCT) and cellular therapy research. Membership encompasses more than 550 centres from over 60 countries that perform or are involved in HSCT.

The EBMT holds a central role in performing co-operative studies and disseminating state-of-the-art knowledge: the aim is to increase survival rates and enhance the quality of life of patients with life-threatening blood cancers and diseases.

The EBMT is built on 3 pillars

1. SCIENCE
2. EDUCATION
3. PATIENT CARE
The EBMT coordinates its scientific activities through ten Working Parties and the Nurses Group:

- **Disease-related**: Acute Leukaemia, Severe Aplastic Anaemia, Autoimmune Diseases, Chronic Malignancies, Inborn Errors and Lymphomas.
- **Transversal**: Paediatrics, Cellular Therapy and Immunobiology, Infectious Diseases and Transplant Complications.

The Working Parties use data from the EBMT patient Registry to perform three types of studies:

1. **Retrospective data collection studies** using data from the Registry, ad-hoc data collections, and centre-based surveys.
2. **Non-interventional cohort studies** based on prospective patients’ registration and data collection. Treatments and medical assessments follow standard hospital protocols.
3. **Interventional studies** (Prospective Clinical Trials) based on a study protocol which determines treatments and medical assessments, including one or more experimental treatment(s).

---

**THE REGISTRY** the backbone of the EBMT

The EBMT patient Registry was established in the early 1970’s. It is the only data source of its kind in Europe. The data are submitted continuously by more than 550 centers, including from outside Europe.

The Registry has data on more than 650,000 HSCT procedures including details on disease, transplant type, donor type and stem cell source. It contains data on patients that have undergone HSCT and also patients receiving immunosuppressive therapies or other cell therapies. The Registry also offers the possibility to enter donors’ follow-up data, which is crucial to ensure maximum donor safety.

The Registry underpins extensive European research that translates into changes in clinical practice and improvements in patient outcome and care.

---

**THE ACTIVITY SURVEY** measuring trends in transplant activity

In 1990, the EBMT introduced the Activity Survey, a novel tool for assessing the real picture of HSCT in Europe. On an annual basis, all EBMT members and affiliated teams report their number of transplant patients by indication, donor type and stem cell source.

The Activity Survey has evolved into a mandatory self-reporting system and it forms an integral part of the international quality assurance programme JACIE.

A second survey on cellular therapies and tissue engineering introduced in 2008 provides an overview of the latest developments in the field of non-HSCT cellular therapies.
ANNUAL MEETING

The EBMT organises an Annual Meeting attended by more than 5,000 participants, including international experts, scientists, physicians, nurses, data managers, statisticians, clinical research technicians, processing laboratory personnel and patients. This important forum ensures and encourages dialogues and information exchange, education and scientific productivity.

The annual Patient, Family and Donor Day aims at exploring the scientific trends and the special relationship which is often created between the clinical BMT personnel and patients and their families.

EDUCATIONAL EVENTS

The EBMT and its Working Parties, Committees and Groups put on specialised educational events throughout the calendar year, offering in-depth content for all of the sub-specialities within BMT.

EDUCATIONAL RESOURCES

The EBMT publishes the top international reference handbooks on HSCT and cellular therapies for clinicians, researchers and nurses: the EBMT Handbook and the EBMT Nurses Textbook.
HAEMATOLOGY AND HSCT NURSING

The EBMT Nurses Group, representing more than 800 nurses and allied health professionals, is one of the leading groups in the field of haematology and HSCT nursing. It is dedicated to improving the care of patients receiving HSCT and promoting excellence in care through evidence-based practice. The Nurses Group’s mission is to enhance and value the nursing role all over the world, supporting and sharing knowledge through communication, advocacy, research, training and education.

STANDARDS AND ACCREDITATION

improving safety and quality in transplant and cellular therapy

The Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) was established in 1998. It promotes high-quality patient care and laboratory performance in the collection, processing and administration of cellular therapy through a profession-led, voluntary accreditation scheme.

JACIE works continuously with international partner organisations to develop and maintain standards for the provision of quality medical and laboratory practice in HSCT, performs on-site inspections, and accredits those programmes that demonstrate compliance with these standards. JACIE also provides training for inspectors and centres on aspects related to the accreditation process.